P-137Intraperitoneal chemotherapy for pancreatic cancer with peritoneal metastases: A single center retrospective analysis of 25 patients

Introduction: Unresectable pancreatic cancer is one of the unfavorable prognosis cancers with merely one year of median overall survival (OS). Furthermore, the prognosis becomes even worse with peritoneal metastases due to reduced delivery capacity of anti-cancer drugs and lots of associated complications. Recently, the efficacy and safety data of intraperitoneal paclitaxel (ip PTX) in combination with systemic chemotherapy for gastric cancer with peritoneal metastases has been published by Ishigami at the ASCO 2016. We have participated in this intraperitoneal chemotherapy study projects and here we applied this strategy to pancreatic cancer with peritoneal metastases.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research